Results
Galderma lifts 2026 sales outlook to 19‑21%
Galderma posted H1 net sales of $3.13 bn, beating the $3.06 bn consensus, with constant‑currency growth of 24.6% versus 22.3% expected.
Core EBITDA reached $802 m (25.6% margin, up 328 bps) and core n
